BJJF078 is an aminopiperidine derivative. BJJF078 is a potent inhibitor of recombinant human and mouse Transglutaminase enzyme (TG2) activity, IC50 values of 41 and 54 nM, respectively. BJJF078 also inhibits the close related enzyme TG1, with an IC50 of 0.16 μM. BJJF078 can be used for Multiple sclerosis (MS) research.

LY 295427 is a LDL receptor modulator and a hypocholesterolemic agent. LY 295427 derepresses the transcription of the LDLR (LDL Receptor). LY 295427 can be used for hypercholesterolemia research.

IMTPPE (SID3712502) is a novel small molecule capable of inhibiting androgen receptor (AR) transcriptional activity (IC50=1 uM) and protein level in C4-2 prostate cancer cells.

RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC50s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely.

CCR2 antagonist 3 is a chemokine receptor 2 (CCR2) antagonist.

Glutaminase-IN-3 (compound 657) is a potent glutaminase inhibitor extracted from patent WO2014089048A1, compound 657, has an IC50 of 0.24 μM for Glutaminase 1 (GLS1).

VT-1598 tosylate is an orally active and selective fungal inhibitor targeting CYP51. VT-1598 tosylate shows anti-fungal activity against C. auris.

BDP8900 (BDP-8900) is a highly potent and selective Myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with IC50 of 43 nM (MRCKβ), >100-fold selectivity over related ROCK1 or ROCK2.

BDP9066 (BDP-9066) is a highly potent and selective Myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with IC50 of 43 nM, >100-fold selectivity over related ROCK1 or ROCK2.

Gefitinib impurity 2 is the impurity of Gefitinib. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity.

10-OH-NBP D4 is deuterium labeled 10-OH-NBP. 10-OH-NBP is a Butylphthalide hydroxylated metabolite and can penetrates the blood-brain barrier (BBB). Butylphthalide exerts neuroprotective effects and has potential for cerebral ischemia research.

4,5-Dichloroveratrole is a chlorinated product formed by reaction of Veratryl alcohol with chlorine dioxide solution.

6,7-Dimethyl-8-ribityllumazine is a direct biosynthetic precursor of Riboflavin. 6,7-Dimethyl-8-ribityllumazine is a noncovalently bound fluorophore of Lumazine protein (LumP), which is a fluorescent accessory protein.

Sevelamer carbonate is an orally active and non-calcium-based phosphate binding agent and used for the hyperphosphatemia of chronic kidney disease (CKD)research. Sevelamer carbonate effectively lowers serum phosphorus levels hile having minimal effect on serum calcium or serum chloride levels in vivo. Sevelamer carbonate is considered as an improved, buffered form of sevelamer.

VT-1161 is a potent, highly-selective, and oral fungal CYP51 inhibitor with Kd of ≤ 39 nM.

15-Keto Travoprost (15-Keto Fluprostenol isopropyl ester) is a metabolite of Travoprost. 15-Keto Travoprost shows stimulatory effect on the growth and thickening of the eyelashes.

Pegozafermin is a fibroblast growth factor FGF21 analog, which is an endogenous metabolic hormone and regulates energy expenditure and glucose and lipid metabolism. Pegozafermin decreases the level of triglyceride (TG), can be used for non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

N-Trimethylchitosan is a water-soluble multifunctional polymer which is a Chitosan derivative. N-Trimethylchitosan can be used for drug delivery and to synthesize nanoparticles.

W-7 isomer hydrochloride is an isomer of W-7 hydrochloride. W-7 hydrochloride is a selective calmodulin antagonist.

4-Chloro-7-fluoropyrrolo[1,2-a]quinoxaline-1-carbaldehyde, a derivative of (E)-7-Fluoro-4-hydrazono-4,5-dihydropyrrolo[1,2-a]quinoxaline.

CCB02 (CCB 02) is a specific small molecule inhibitor of CPAP-tubulin interaction with IC50 of 0.689 uM in AlphaScreen assay, selectively binds at the CPAP binding site of tubulin.

(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations.

VL-6 can be used in the synthesis of biomimetic nanomaterials which for delivery of therapeutic, diagnostic, or prophylactic agents.

WEHI-539 is a highly potent and selective BCL-XL inhibitor. The prosurvival BCL-2 family protein BCL-X(L) is often overexpressed in solid tumors and renders malignant tumor cells resistant to anticancer therapeutics. WEHI-539 has high affinity (subnanomolar) and selectivity for BCL-X(L) and potently kills cells by selectively antagonizing its prosurvival activity. WEHI-539 will be an invaluable tool for distinguishing the roles of BCL-X(L) from those of its prosurvival relatives, both in normal cells and notably in malignant tumor cells, many of which may prove to rely upon BCL-X(L) for their sustained.

MMAF-Ome belongs to ADC, and inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4-) cell lines, respectively.

Toyocamycin (Vengicide) is an adenosine analog produced by Actinomycete, acts as an XBP1 inhibitor, inhibits IRE1α-induced ATP-dependent XBP1 mRNA cleavage, with an IC50 of 80 nM. Toyocamycin (Vengicide) induces apoptosis. Toyocamycin (Vengicide) shows no effect on IRE1α auto-phosphorylation[1].

Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis.

1-β-D-Arabinofuranosylcytosine, a cytosine analogue, inhibits DNA polymerases α, δ, and ε, and RNA polymerases resulting in suppression of DNA synthesis and repair. 1-β-D-Arabinofuranosylcytosine acts as an antimetabolic agent which is responsible for dam

DS-6051b is a potent and selective ROS1 and TRK family inhibitor with IC50 of 0.207 nM, 0.622 nM and 0.980 nM against ROS1, NTRK1 and NTRK3. DS-6051b especially inhibits ROS1 G2032R and other crizotinib-resistant ROS1 mutants.

Moracin M is a phosphodiesterase-4 inhibitor isolated from Morus alba. Moracin M has anti-inflammatory activity. Moracin M inhibits lipopolysaccharide-induced inflammatory responses in nucleus pulposus cells via regulating PI3K/Akt/mTOR phosphorylation. Moracin M inhibits airway inflammation by interrupting the JNK/c-Jun and NF-κB pathways in vitro and in vivo.